Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma

Physics in Medicine and Biology

Volumn 55, Issue 23, 2010, Pages 7055-7065

  Taddei, Phillip J ^a   Howell, Rebecca M ^a   Krishnan, Sunil ^a   Scarboro, Sarah B ^a   Mirkovic, Dragan ^a   Newhauser, Wayne D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATTRIBUTABLE RISKS; GLOBAL HEALTH; HEPATOCELLULAR CARCINOMA; INTENSITY-MODULATED PHOTON RADIOTHERAPIES; INTENSITY-MODULATED RADIATION THERAPY; LATE EFFECTS; LIVER TISSUE; PHOTON BEAMS; PRIMARY RADIATIONS; PROTON BEAM THERAPY; RADIATION DOSE; RADIATION-INDUCED LIVER DISEASE; RISK MODEL; SIDE EFFECT; STRAY RADIATION; THERMOLUMINESCENT DOSIMETERS; TREATMENT PLANNING SYSTEMS;

DOSIMETRY; HEALTH RISKS; HISTOLOGY; LIVER; PHOTONS; PROTON BEAMS; PROTONS; RADIOTHERAPY; RISK ASSESSMENT; TUMORS;

PHYSICAL THERAPY;

PROTON;

ARTICLE; COMPARATIVE STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; ORGANS AT RISK; PHOTON; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RISK ASSESSMENT;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; ORGANS AT RISK; PHOTONS; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT;

EID: 78650036413     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/55/23/S07     Document Type: Article

References (34)

1. Agosteo S, Birattari C, CaravaggioM, SilariMand Tosi G 1998 Secondary neutron and photon dose in proton therapy Radiother. Oncol. 48 293-305
2. Altekruse S F, McGlynn K A and Reichman M E 2009 Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005 J. Clin. Oncol. 27 1485-91
3. Brenner D J, Elliston C D, Hall E J and Paganetti H 2009 Reduction of the secondary neutron dose in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator Phys. Med. Biol. 54 6065-78
4. Chiba T et al 2005 Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients Clin. Cancer Res. 11 3799-805
5. Chofor N, Harder D, Ruhmann A,Willborn K C,Wiezorek T and Poppe B 2010 Experimental study on photon-beam peripheral doses, their components and some possibilities for their reduction Phys. Med. Biol. 55 4011-27
6. Dawson L A 2009 Protons or photons for hepatocellular carcinoma? Let's move forward together Int. J. Radiat. Oncol. Biol. Phys. 74 661-3
7. Fontenot J D, Lee A K and Newhauser W D 2009 Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 74 616-22
8. Fontenot J D, Taddei P, Zheng Y, Mirkovic D, Jordan T and Newhauser W D 2008 Equivalent dose and effective dose from stray radiation during passively scattered proton radiotherapy for prostate cancer Phys. Med. Biol. 53 1677-88 (Pubitemid 351423004)
9. Garcia M, Jemal A, Ward E M, Center M M, Hao Y, Siegel R L and Thun M J 2007 Global Cancer Facts & Figures 2007 (Atlanta, GA: American Cancer Society)
10. Horner M J et al (ed) 2008 SEER Cancer Statistics Review 1975-2006 (Bethesda, MD: National Cancer Institute)
11. Howell R M, Hertel N E, Wang Z, Hutchinson J and Fullerton G D 2006 Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV and 18 MV beam energies Med. Phys. 33 360-8
12. Howell R M, Scarboro S B, Taddei P J, Krishnan S, Kry S F and NewhauserWD 2010 Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy Phys. Med. Biol. 55 7009-23
13. ICRP 1991 Recommendations of the International Commission on Radiological Protection. Publication 60 Ann. ICRP 21
14. ICRP 2003 Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Publication 92 Ann. ICRP 33
15. Krishnan S, Dawson L A, Seong J, Akine Y, Beddar S, Briere T M, Crane C H and Mornex F 2008 Radiotherapy for hepatocellular carcinoma: an overview Ann. Surg. Oncol. 15 1015-24
16. Kry S F, Vassiliev O N and Mohan R 2010 Out-of-field photon dose following removal of the flattening filter from a medical accelerator Phys. Med. Biol. 55 2155-66
17. Llovet J M 2005 Updated treatment approach to hepatocellular carcinoma J. Gastroenterol. 40 225-35
18. NCRP 1993 Limitation of exposure to ionizing radiation NCRP Report 116 (Bethesda, MD: National Council on Radiation Protection and Measurements)
19. Newhauser W, Fontenot J, Zheng Y, Polf J, Titt U, Koch N, Zhang X and Mohan R 2007a Monte Carlo simulations for configuring and testing an analytical proton dose- alculation algorithm Phys. Med. Biol. 52 4569-84
20. Newhauser W et al 2007b A Monte-Carlo based dose engine for proton radiotherapy treatment planning Med. Phys. 34 2406
21. Newhauser W D et al 2009 The risk of developing a second cancer after receiving craniospinal proton irradiation Phys. Med. Biol. 54 2277-91
22. NewhauserWD, Giebeler A, Langen K M, Mirkovic D and Mohan R 2008a Can megavoltage computed tomography reduce proton range uncertainties in treatment plans for patients with large metal implants? Phys. Med. Biol. 53 2327-44
23. Newhauser W D, Zheng Y, Taddei P J, Mirkovic D, Fontenot J D, Giebeler A, Zhang R, Titt U and Mohan R 2008b Monte Carlo proton radiation therapy planning calculations T. Am. Nucl. Soc. 99 63-4
24. NRC (National Research Council) 2006 Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII-Phase 2 (Washington, DC: National Academies Press)
25. PelowitzDB(ed) 2008MCNPX™ User's Manual, Version 2.6.0 (Los Alamos, NM: LosAlamos National Laboratory)
26. Perz J F, Armstrong G L, Farrington L A, Hutin Y J and Bell B P 2006 The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J. Hepatol. 45 529-38
27. Taddei P J, Fontenot J D, Zheng Y, Mirkovic D, Lee A K, Titt U and Newhauser W D 2008 Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer Phys. Med. Biol. 53 2131-47 (Pubitemid 351605990)
28. Taddei P J, Krishnan S, Mirkovic D, Yepes P and Newhauser W D 2009a Effective dose from stray radiation for a patient receiving proton therapy for liver cancer AIP Conf. Proc. 1099 445-9
29. Taddei P J, Mirkovic D, Fontenot J D, Giebeler A, Zheng Y, Kornguth D, Mohan R and Newhauser W D 2009b Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams Phys. Med. Biol. 54 2259-75
30. Taddei P J, Mirkovic D, Fontenot J D, Giebeler A, Zheng Y, Kornguth D, Mohan R and Newhauser W D 2009c Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams Phys. Med. Biol. 54 2259-75
31. Taddei P J, Mirkovic D, Fontenot J D, Giebeler A, Zheng Y, Titt U, Woo S and Newhauser W D 2009d Reducing stray radiation dose for a pediatric patient receiving proton craniospinal irradiation Nucl. Technol. 168 108-12
32. Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane C H, Martel M, Gillin M, Mohan R and Beddar S 2008 Proton radiotherapy for liver tumors: dosimetric advantages over photon plans Med. Dosim. 33 259-67
33. Zheng Y, Fontenot J, Taddei P, Mirkovic D and Newhauser W 2008 Monte Carlo simulations of neutron spectral fluence, radiation weighting factor and ambient dose equivalent for a passively scattered proton therapy unit Phys. Med. Biol. 53 197-201
34. Zurlo A, Lomax A, Hoess A, Bortfeld T, Russo M, Goitein G, Valentini V, Marucci L, Capparella R and Loasses A 2000 The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors Int. J. Radiat. Oncol. Biol. Phys. 48 277-88